NEW YORK (AP) — Biotechnology company Amgen says its second-quarter net income slipped 5 percent, mainly on higher income taxes, as sales of anemia drugs again lost ground in the market.
The Thousand Oaks, Calif., company earned $1.2 billion, down from $1.3 billion a year prior, though results remained flat at $1.25 per share. Revenue rose 2 percent to $3.8 billion from $3.7 billion.
Excluding charges, though, the company earned $1.38 per share, topping Wall Street expectations for $1.30 per share on $3.74 billion in revenue.
Sales of the anemia drug Aranesp fell 13 percent to $603 million.
